Latest Renal cell carcinoma Stories
SARASOTA, Fla., July 14, 2011 /PRNewswire/ -- Elliot Hatton was on a cruise celebrating his 25th wedding anniversary when he noticed blood in his urine. He mentioned it to his wife, but since it didn't happen again, he ignored it.
EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking AfinitorÂ® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6).
(Ivanhoe Newswire) "“ A new study reveals that cancer patients treated with the drugs sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared. "The damage that chemotherapy does to normal, healthy cells as it treats cancer has been well documented, but the precise effect that the new class of targeted agents has on the immune system is less well known. This study helps us answer that question," Keith...
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared.
ATLANTA, June 21, 2011 /PRNewswire/ -- MDOUTLOOKÂ®, the global oncology intelligence initiative powered by The Arcas Group, announced results from 4th Annual Quick Poll research launched immediately following this month's annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
TUEBINGEN, Germany, June 15, 2011 /PRNewswire/ -- igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC). The trial is designed to demonstrate the overall survival benefit of IMA901 in...
About 50,000 Americans are diagnosed with kidney cancer every year, but a new form of radioimmuntherapy may decrease this number significantly.
DURHAM, N.C., June 5, 2011 /PRNewswire/ -- Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis(TM) immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.
Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems.
DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis(TM) immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.